El Grupo Grünenthal

Josefina Mendoza

The term ‘pharmacogenomics’ emerged in the early 2000s to encompass the broader study of how genetic variations influence drug response, including not only drug metabolism but also drug targets and pharmacodynamics. Advances in genomic technologies and bioinformatics have accelerated the discovery of genetic variants associated with response to a wide range of drugs.

Surveillance of drug safety concerning individual genetic variances in drug metabolism is key for pharmacogenomics.

Healthcare professionals may effectively mitigate risks associated with genetic variations and drug response, ultimately improving the quality of patient care and treatment outcomes. It involves a multidisciplinary approach that integrates genetics, pharmacology, epidemiology, and regulation to ensure the safe and effective use of drugs in genetically diverse populations.

History of Pharmacogenomics

In the 1950s-1970s studies in ‘pharmacogenetics’ focused on genetic variations and their influence on drug responses. During this time, researchers focused on identifying genetic variants associated with drug metabolism pathways, such as those involving drug-metabolizing enzymes like cytochrome P450.

In 2003 the completion of the Human Genome Project marked a significant milestone in the field of pharmacogenomics. This project provided a comprehensive map of the human genome, facilitating the identification of genetic variants associated with drug response and laying the foundation for personalized medicine approaches.

Role of Pharmacovigilance in Pharmacogenomics

Some key aspects of patient safety monitoring in pharmacogenomics include the collection and analysis of adverse drug reactions (ADRs) associated with pharmacogenomic factors. Monitoring the results of genetic testing allows healthcare providers to tailor treatment schemes to individual patient profiles. Genetic testing (preventive or reactive) may be conducted to identify patients who may be at higher risk of adverse drug reactions or treatment failure due to specific genetic variations. Gene therapy clinical systems integrated into electronic health record systems can provide real-time guidance to healthcare providers based on patients' genetic profiles. These systems can alert providers to potential drug-gene interactions, recommend alternative medications, or suggest dosage adjustments to minimize the risk of adverse events. Training programs can enhance patient safety by ensuring the appropriate use of genetic information in treatment planning.

Deep research and surveillance efforts are essential for identifying new pharmacogenomic associations, assessing the clinical validity and utility of genetic testing, and monitoring long-term safety outcomes in realworld patient populations. Largescale studies and pharmacovigilance initiatives contribute to our understanding of the safety implications of pharmacogenomics.

Patient engagement plays an active role in monitoring their own safety in pharmacogenomics raising awareness about the importance of genetic testing and targeting a personalized treatment.

Challenges for Pharmacogenomics

Integration into clinical workflows from cross-functional healthcare providers qualified to interpret genetic test results and incorporate them into treatment decisions. Additionally, electronic health record systems must be adapted to accommodate pharmacogenomic data. Data privacy and security, pharmacogenomic testing generates sensitive genetic information that raises concerns about patient privacy and data security. The cost-effectiveness of testing and reimbursement models need to be carefully evaluated.

Challenges for Applicability of Pharmacovigilance in Pharmacogenomics

Genetic testing integration into pharmacovigilance practices allows for personalized drug therapy approaches. Generation of regulatory guidelines for ‘Pharmacogenomics and Pharmacovigilance’ are required to evaluate the safety and efficacy of pharmacogenomicbased therapies, and monitor post-market safety through pharmacovigilance activities such as the assessment and validation of genetic variations of the adverse drug reactions (ADRs) associated with genetic biomarkers specific to drug responses considering pharmacogenomic factors. Post-marketing surveillance in real-world populations assessing the risk of adverse events associated with specific drugs in individuals with certain genetic profiles is the key to aiming risk assessment and its management considering new associations between genetic variations and drug responses. The vision of consolidation of key data and collaboration among stakeholders shall improve understanding of the impact of genetic variations on drug safety and efficacy.

Future of Pharmacogenomics and Patient Safety

Overall, the potential of pharmacogenomics is bright, with the potential to significantly improve patient outcomes, reduce healthcare costs, and advance the practice of personalized and precise medicine. This personalized approach can improve treatment outcomes by minimizing adverse drug reactions and optimizing efficacy. Patients may need to understand the implications of their genetic results on drug therapy decisions for shared decisionmaking with their healthcare providers.

Pharmacogenomic testing will be more accessible and affordable with AI advances in sequencing technology and bioinformatics. Large-scale population-level studies, such as biobanks and genome-wide association studies may generate vast amounts of genetic data that may be used to identify and improve new pharmacogenomic associations. These studies will further enhance understanding of the genetic factors influencing drug response.

Advances in pharmacogenomics are driving the development of targeted therapies designed to treat diseases based on specific genetic mutations or variations. Healthcare providers may be selecting the most appropriate drug and dose for individual patients based on their genetic makeup. Pharmacogenomics has the potential to shift medicine towards a more preventative model by identifying individuals at higher risk of adverse reactions to specific drugs before they are prescribed.